Key facts
- Notable investors include Capital Development Investment Fund (China).
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for PolyGene Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for PolyGene Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PolyGene Bio
Manufacturer of gene delivery materials focused on the development and production of polymer-based transfection reagents for cell and gene therapy applications. The company produces gene transfection reagents, polymer delivery vectors, nucleic acid delivery materials, biomedical polymers and transfection technologies that serve biotechnology companies and research institutions and enable efficient gene delivery and therapeutic development.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2025
- Website
- polygenework.com/
- Ownership
- Privately Held (backing)
PolyGene Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PolyGene Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PolyGene Bio in its N-PORT filings yet. We sweep new filings monthly.